NASONEX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nasonex, and what generic alternatives are available?
Nasonex is a drug marketed by Organon Llc and Perrigo Pharma Intl and is included in two NDAs.
The generic ingredient in NASONEX is mometasone furoate. There are thirty drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nasonex
A generic version of NASONEX was approved as mometasone furoate by PADAGIS US on March 18th, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NASONEX?
- What are the global sales for NASONEX?
- What is Average Wholesale Price for NASONEX?
Summary for NASONEX
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 79 |
| Clinical Trials: | 60 |
| Patent Applications: | 4,548 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for NASONEX |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NASONEX |
| What excipients (inactive ingredients) are in NASONEX? | NASONEX excipients list |
| DailyMed Link: | NASONEX at DailyMed |
Recent Clinical Trials for NASONEX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Yingu Pharmaceutical Co., Ltd | Phase 4 |
| Centre hospitalier de l'Université de Montréal (CHUM) | Phase 4 |
| EMS | Phase 3 |
Paragraph IV (Patent) Challenges for NASONEX
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| NASONEX | Nasal Spray | mometasone furoate | 50 mcg/ Spray | 020762 | 1 | 2009-08-07 |
US Patents and Regulatory Information for NASONEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Organon Llc | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Perrigo Pharma Intl | NASONEX 24HR ALLERGY | mometasone furoate | SPRAY, METERED;NASAL | 215712-001 | Mar 17, 2022 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NASONEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Organon Llc | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Organon Llc | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Organon Llc | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Organon Llc | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for NASONEX
See the table below for patents covering NASONEX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Denmark | 0740550 | ⤷ Sign Up | |
| Croatia | P920383 | MOMETASONE FUROATE MONOHYDRATE, PROCESS FOR MAKING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAID COMPOUND | ⤷ Sign Up |
| Japan | H11286447 | USE OF MOMETASONE FUROATE FOR TREATMENT OF DISEASES OF AIRWAY PASSAGE AND LUNG | ⤷ Sign Up |
| Yugoslavia | 48666 | ⤷ Sign Up | |
| Denmark | 39082 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for NASONEX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0548114 | 19875032 | Germany | ⤷ Sign Up | PRODUCT NAME: MOMETASON-FUROAT-MONOHYDRAT; NAT. REGISTRATION NO/DATE: 40803.00.00 19980218; FIRST REGISTRATION: FRANKREICH NL 22055 19970219 |
| 0548114 | 5/1998 | Austria | ⤷ Sign Up | PRODUCT NAME: MOMETASON FUROAT MONOHYDRAT; NAT. REGISTRATION NO/DATE: 1-22208 19971111; FIRST REGISTRATION: FR AMM 343012.6 19970219 |
| 3043773 | 132021000000191 | Italy | ⤷ Sign Up | PRODUCT NAME: MOMETASONE O UN SUO SALE E OLOPATADINA O UN SUO SALE(RYALTRIS); AUTHORISATION NUMBER(S) AND DATE(S): 048499014, 048499026, 048499038, 20210726;140638, 20210426 |
| 0548114 | SPC/GB97/064 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410 |
| 0057401 | SPC/GB93/085 | United Kingdom | ⤷ Sign Up | SPC/GB93/085, EXPIRES: 20050621 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
